Blog

$Andrius Žučenka: Stop by at our EHA2024 poster on relapsed/refractory AML$

Photo of Andrius Žučenka from vjhemonc.com

Jun 16, 2024, 02:39

Andrius Žučenka: Stop by at our EHA2024 poster on relapsed/refractory AML

Andrius Žučenka, Head of The Department of Specialized Care For Immunocompromised Patients at VUL Santaros Klinikos, shared a post on X:

“Please stop by at our EHA2024 poster P1325 with the results of the non-intensive, targeted therapy-based preconditioning regimens followed by standard conditioning and alloSCT in relapsed/refractory AML/HR-MDS patients with active disease (including TP53m/post-Ven).”

$Andrius Žučenka: Stop by at our EHA2024 poster on relapsed/refractory AML$

Source: Andrius Žučenka/X

active disease alloSCT Andrius Žučenka cancer EHA2024 HR-MDS OncoDaily Oncology P1325 post-Ven preconditioning regimens R/R AML standard conditioning targeted therapy TP53m

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage